BioPorto A/S (CPH: BIOPOR)
Market Cap | 792.29M |
Revenue (ttm) | 33.83M |
Net Income (ttm) | -50.02M |
Shares Out | 429.66M |
EPS (ttm) | -0.13 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 328,846 |
Open | 1.852 |
Previous Close | 1.866 |
Day's Range | 1.844 - 1.860 |
52-Week Range | 1.200 - 3.850 |
Beta | 1.25 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Oct 30, 2024 |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was... [Read more]
Financial Performance
In 2023, BioPorto's revenue was 30.96 million, an increase of 6.87% compared to the previous year's 28.97 million. Losses were -56.33 million, -25.81% less than in 2022.
Financial StatementsNews
BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024
August 15, 2024 Announcement no. 18 BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024 Continued strong growth in US sales of NGAL tests and fo...
BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting
August 7, 2024 News Release BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, August 7, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPor...
BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms
July 30, 2024 News Release BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms ADLM 2024 Conference – Chic...
BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo
July 29, 2024 News Release BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo ADLM 2024 Conference – Chicago, July 29, 2024 – BioPorto Diagnostics, a company speciali...
BioPorto confirms market acceptance of NGAL products with US standing order.
July 1, 2024 News Release BioPorto confirms market acceptance of NGAL products with US standing order. COPENHAGEN, Denmark and BOSTON, MA, USA, July 1, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPo...
Changes of number of shares and votes in BioPorto A/S
June 24, 2024 Announcement no. 15 Changes of number of shares and votes in BioPorto A/S.
Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
June 18, 2024 Announcement no. 14 Private placement of 50,000,000 new shares oversubscribed - gross proceeds of DKK 81.4 million, corresponding to USD 11.7 million, to BioPorto A/S.
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price.
June 17, 2024 Announcement no. 13 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH ...
BioPorto A/S Appoints Chief Financial Officer
May 30, 2024 Announcement no. 12 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Niels Høy Nielsen as its new Executive Vice Presi...
First Quarter 2024: Strong growth in US sales of The NGAL Test
May 8, 2024 Announcement no. 11 First Quarter 2024: Strong growth in US sales of The NGAL Test COPENHAGEN, Denmark and BOSTON, MA, USA, May 8, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no.
BioPorto A/S Appoints President and CEO of BioPorto Inc.
May 7, 2024 News release BioPorto A/S Appoints President and CEO of BioPorto Inc. COPENHAGEN, DENMARK and BOSTON, MA, USA, May 7, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOP...
BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting
May 2, 2024 News release BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA, USA, May 2, 2024 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or...
BioPorto A/S Appoints Chief Legal Officer
April 10, 2024 Announcement no. 8 BioPorto A/S Appoints Chief Legal Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 10, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR)...
Notice convening the Annual General Meeting in BioPorto A/S
April 4, 2024 Announcement no. 6 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Compa...
Correction: BioPorto Announces Annual Results for 2023
Correction: Updated Annual Report attached April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioP...
BioPorto Announces Annual Results for 2023
April 4, 2024 Announcement no. 05 BioPorto Announces Annual Results for 2023 COPENHAGEN, DENMARK and BOSTON, MA, USA, April 4, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR)...
BioPorto A/S to Host Annual Earnings Webcast
April 2, 2024 News release BioPorto A/S to Host Annual Earnings Webcast COPENHAGEN, DENMARK and BOSTON, MA, USA, April 2, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an ...
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer
April 2, 2024 Announcement no. 04 BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer COPENHAGEN, DENMARK and BOSTON, MA, USA, April 2, 2024, (GLOBE NEWSWIRE) -- BioPorto ...
BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026
February 22, 2024 Announcement no. 03 BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 COPENHAGEN, DENMARK and BOSTON, MA, February 22, 2024, (GLO...
Roche Diagnostics and BioPorto expand collaboration
20 February 20, 2024 Announcement no. 02 Roche Diagnostics and BioPorto expand collaboration COPENHAGEN, DENMARK and BOSTON, MA, 20 February, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Com...
BioPorto A/S to host investor meetings on 22 February 2024
19 February 2024 News Release BioPorto A/S to host investor meetings on 22 February 2024 COPENHAGEN, DENMARK and BOSTON, Mass., 19 February 2024, BioPorto A/S (BioPorto or Company), an in vitro diagno...
BioPorto implements changes to the Executive Management.
January 9, 2024 Announcement no. 01 BioPorto implements changes to the Executive Management.
BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år
8. december 2023 Pressemeddelelse BioPorto modtager FDA godkendelse i USA vedrørende NGAL Test til identificering af risiko for akut nyresvigt hos børn i alderen 3 måneder til 21 år BioPorto A/S har i...
BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years
December 7, 2023 Announcement no. 20 BioPorto Receives FDA 510(k) Clearance for NGAL Test in the United States First Test to Aid in Assessing AKI Risk for Patients Aged 3 Months Through 21 Years COPEN...
BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference
November 1, 2023 News Release BioPorto Announces Two Poster Presentations at ASN Kidney Week 2023 Conference COPENHAGEN, Denmark and BOSTON, MA, USA, November 1, 2023, (GLOBE NEWSWIRE) -- BioPorto A/...